Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yabao Partners with Salus Pharma to Develop Difficult-to-Make Generics

publication date: Apr 20, 2016
Yabao Pharma of Shanghai partnered with Salus Pharma, a privately held New Jersey generic drug maker, to co-develop, make and commercialize high-barrier-to-entry generic drugs worldwide. Salus specializes in extended-release products. Yabao will own rights to specified Salus Pharma-developed products outside the US. Yabao will also manufacture those drugs for global markets, while Salus will retain the right to commercialize the products in the US. Financial terms were not disclosed. Yabao will be attending the ChinaBio® Partnering Forum, May 18-19 in Suzhou. More details....

Stock Symbol: (SHA: 600351)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital